Friday, April 19, 2024
HomeIndiaSII will sell vaccine for Rs 200 to govt, Rs 1,000 to...

SII will sell vaccine for Rs 200 to govt, Rs 1,000 to public: Report

The Oxford vaccine will be sold for Rs 200 per dose to the government while it will be available for Rs 1,000 for the general public, Adar Poonawalla, chief executive of Serum Institute of India, was quoted as saying by a TV channel on Sunday.


His comments come after the country’s drug regulator cleared its Covishield vaccine for emergency approval in Poonawalla said that Covishield vaccine, developed by in partnership with the and pharma major AstraZeneca, is “safe and effective” against coronavirus.



According to Poonawalla, his firm is making between 50 and 60 million doses a month of the AstraZeneca/Oxford vaccine, which is cheaper than the Pfizer-BioNTech jab and easier to store and transport. He said that his company is waiting to get into an agreement with the government and added that the vaccine will be rolled out in the next 7-10 days.


Poonawalla said that Serum Institute has the capacity to manufacture 5,000 doses of vaccine per minute and already 40 to 50 million doses of the vaccine is ready for dispatch. Speaking on exporting Oxford vaccine to other countries, Poonawalla said that his company is in bilateral agreement with Bangladesh, Saudi Arabia and 66 other countries and will also look towards exporting the vaccine to them soon after India’s vaccination drive is in advanced stage.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor



Source link

- Advertisment -